Pond Street Ledger

MoonPay Buys a Registered Broker-Dealer to Get Into Tokenised Securities

The payments firm agreed an all-stock deal worth more than $60m for North Capital, an SEC-registered broker-dealer, days after the SEC opened a conditional path for tokenised stock trading.

✓ 1450.efrogs.eth2026-09-244 min
Sources: Cointelegraph, CoinDesk, The Defiant, The Defiant, Cointelegraph

MoonPay, the crypto payments company best known for card-to-wallet purchase rails, has agreed to acquire North Capital in an all-stock transaction. Sources told CoinDesk the deal is worth more than $60m, and it remains subject to regulatory approval. North Capital is registered with the Securities and Exchange Commission as a broker-dealer, the licence a firm needs in the United States to trade securities on behalf of others.

What MoonPay is buying is the permission set, not a customer book. A broker-dealer registration, with the associated trading and investment infrastructure, is the piece a crypto company cannot build and cannot borrow. It has to be acquired or applied for, and applications take time that a fast-moving regulatory window does not give. Chief executive Ivan Soto-Wright framed the purchase around supporting wider adoption of tokenised real-world assets, according to CoinDesk.

Why the timing is not a coincidence

Last Thursday the SEC issued a five-year conditional exemption allowing tokenised National Market System stock, meaning ordinary listed US equities, to trade on permissioned automated market makers, The Defiant reported. An automated market maker is a pool-based trading venue where prices come from a formula rather than an order book. Permissioned means the pool checks who is allowed in. On the same day, Commodity Futures Trading Commission staff extended introducing-broker relief to passive software.

The exemption does not abolish the securities laws. It creates a defined path, for a defined period, for venues that meet its conditions. Every condition has to be met by a regulated entity somewhere in the stack, and firms that already hold registrations are in a materially different position from firms that do not. That is the arithmetic driving a $60m all-stock purchase of a licence-holding business by a payments company.

The shape of the buy side

MoonPay is not alone in the move. Blockchain.com and NYSE Group have signed a preliminary agreement to give the exchange's users access to tokenised US stocks and exchange-traded funds, pending regulatory approval, with the arrangement pointing at NYSE's planned digital venue. Arch Lending, a crypto lender, said on Cointelegraph's Chain Reaction podcast that it intends to move into tokenised equities as onchain stocks gain traction as collateral, according to Cointelegraph.

Those are three different bets on the same premise, placed within a week of each other. One buys the licence, one rents the venue, one builds the credit product on top. All of them assume the SEC's window is real enough to spend money against before the first tokenised NMS share trades on a permissioned pool.

The unresolved question underneath

The industry has not settled what a tokenised stock should be. The Defiant's podcast framed the choice as it stands after the exemption: a synthetic instrument that tracks a share price, or a direct claim on an actual underlying share held somewhere. The two have different disclosure requirements, different failure modes and different answers to the question of what a holder owns if the issuer stops operating.

That choice determines whether a broker-dealer registration is the central asset or a supporting one. If tokenised equities settle on direct claims, the chain of registered intermediaries between the token and the share matters enormously, and North Capital is worth what MoonPay paid. If the market goes synthetic, the licence buys less. The deal is a vote, in stock, on the first answer.

We report facts in our own words and link to the reporting we drew them from. We do not reproduce a source's prose, headline or images. Nothing here is investment advice.